Peripheral & Cranial Nerve Stimulation

Medtronic announced that the American Medical Association has approved new Category I Current Procedural Terminology codes for two of its technologies, the Altaviva implantable tibial neuromodulation device for urge urinary incontinence and the Symplicity Spyral renal denervation system for uncontrolled hypertension. The new codes, which replace existing Category III codes, take effect in January 2028. Category I codes are permanent codes assigned to procedures the AMA deems well established, widely performed across the United States, and supported by robust clinical evidence, and while they can help support physician payment and inform commercial payer coverage decisions, they do not determine coverage, reimbursement, clinical superiority, or patient access. The Altaviva device was approved by the U.S. Food and Drug Administration in September 2025 for urge urinary incontinence, a condition affecting 16 million adults in the United States, and is placed under the skin near the ankle in a minimally invasive procedure. The Symplicity Spyral system was finalized for Medicare coverage in October 2025, and Medtronic said its SPYRAL HTN global clinical program is the most comprehensive studying renal denervation, with more than 5,000 patients and experience in over 40,000 patients globally.

Neuromod Devices has announced the appointment of Joe Ghiz as Chief Commercial Officer and Shannon Basham as VP of Channel Development. Ghiz joins Neuromod's senior management team and will lead the company's global commercial function as it continues to strengthen its position as the category creator in tinnitus care, with CEO Dr. Ross O'Neill citing robust clinical evidence, global regulatory approval, and broad commercial adoption as positioning the company for rapid scaling to address the needs of 740 million tinnitus sufferers worldwide. Ghiz joins from Align Technology, the company behind Invisalign, where he helped create and scale the clear aligner category and built a $10 billion company, and previously spent over a decade at Johnson & Johnson Vision Care in leadership roles spanning sales, marketing, and business development. Basham brings more than 20 years of experience in the hearing care industry, having most recently served as Senior Director of Audiology for Sonova Group in the United States of America, where she was the market-facing head of audiology for the Phonak and Unitron wholesale businesses. The appointments support Neuromod's goal of positioning its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire, as a new standard of care in ENT and audiology practices.